Mutations of
METTL3
biomarker
muscle-invasive bladder cancer
neoadjuvant chemotherapy
pathological response
Journal
Journal of clinical and translational research
ISSN: 2424-810X
Titre abrégé: J Clin Transl Res
Pays: Singapore
ID NLM: 101667205
Informations de publication
Date de publication:
26 Jun 2021
26 Jun 2021
Historique:
received:
12
11
2020
revised:
27
01
2021
accepted:
10
05
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
7
2021
Statut:
epublish
Résumé
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES) to identify genetic mutations in MIBC that can predict NAC response. Forty MIBC patients were enrolled in this study, in which 33 were successfully examined by WES and Sanger sequencing in the discovery cohort ( In the discovery cohort, the mutation frequencies of The somatic mutation of MIBC patients bearing mutated
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES) to identify genetic mutations in MIBC that can predict NAC response.
METHODS
METHODS
Forty MIBC patients were enrolled in this study, in which 33 were successfully examined by WES and Sanger sequencing in the discovery cohort (
RESULTS
RESULTS
In the discovery cohort, the mutation frequencies of
CONCLUSION
CONCLUSIONS
The somatic mutation of
RELEVANCE FOR PATIENTS
UNASSIGNED
MIBC patients bearing mutated
Identifiants
pubmed: 34239995
pii: jctres.07.202103.009
pmc: PMC8259609
Types de publication
Journal Article
Langues
eng
Pagination
386-413Informations de copyright
Copyright: © Whioce Publishing Pte. Ltd.
Références
Genome Med. 2015 Jul 29;7(1):80
pubmed: 26221189
EBioMedicine. 2018 Sep;35:198-203
pubmed: 29941343
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Lancet Oncol. 2018 Dec;19(12):e683-e695
pubmed: 30507435
Cold Spring Harb Protoc. 2015 Mar 11;2015(7):626-33
pubmed: 25762417
JAMA Oncol. 2015 Jul;1(4):466-74
pubmed: 26181256
Mol Cancer. 2019 Jun 22;18(1):110
pubmed: 31228940
J Transl Med. 2019 Apr 8;17(1):116
pubmed: 30961610
Urol Clin North Am. 2020 Feb;47(1):35-46
pubmed: 31757298
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
Nat Rev Clin Oncol. 2018 Jun;15(6):353-365
pubmed: 29599476
Eur Urol. 2016 Mar;69(3):384-8
pubmed: 25636205
Annu Rev Pathol. 2016 May 23;11:149-74
pubmed: 26907529
Eur Urol. 2004 Mar;45(3):297-303
pubmed: 15036674
Nat Rev Urol. 2017 Jun;14(6):348-358
pubmed: 28290459
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Chin J Cancer. 2015 Feb;34(2):61-9
pubmed: 25322863
Eur Urol Oncol. 2018 May;1(1):83-90
pubmed: 31100232
PLoS One. 2007 Aug 01;2(7):e657
pubmed: 17668045
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Cell Res. 2018 May;28(5):507-517
pubmed: 29686311
Trends Cancer. 2019 Jul;5(7):426-439
pubmed: 31311657
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Sci Rep. 2018 Oct 30;8(1):16000
pubmed: 30375428
J Hematol Oncol. 2019 Dec 9;12(1):135
pubmed: 31818312
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Eur Urol Focus. 2020 Jul 15;6(4):632-638
pubmed: 31987763
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704
pubmed: 26664503
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
Eur Urol. 2015 Dec;68(6):959-67
pubmed: 26238431
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2014 Dec 15;20(24):6605-17
pubmed: 25316812
Anticancer Res. 2017 Nov;37(11):6453-6458
pubmed: 29061832
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179